Astaxanthin-Loaded Stealth Lipid Nanoparticles (AST-SSLN) as Potential Carriers for the Treatment of Alzheimer’s Disease: Formulation Development and Optimization

Nanomaterials

Debora Santonocito¹  Giovanni Sposito¹  Carmelo Puglia¹  Giuseppina Raciti¹  Agata Campisi¹  Annamaria Panico¹  MariaGrazia Sarpietro¹  EdyAngela Siciliano¹  Elisabetta Damiani² 

[1] Department of Drug Science and Health, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy;Department of Life and Environmental Sciences, Polytechnic University of Marche, 60121 Ancona, Italy;

关键词: astaxanthin;    stealth system;    SLN;    Alzheimer’s disease;    ORAC;    parenteral administration;   

DOI  :  10.3390/nano11020391

来源: DOAJ

【 摘 要 】

Alzheimer’s disease (AD) is a neurodegenerative disorder associated with marked oxidative stress at the level of the brain. Recent studies indicate that increasing the antioxidant capacity could represent a very promising therapeutic strategy for AD treatment. Astaxanthin (AST), a powerful natural antioxidant, could be a good candidate for AD treatment, although its use in clinical practice is compromised by its high instability. In order to overcome this limit, our attention focused on the development of innovative AST-loaded stealth lipid nanoparticles (AST-SSLNs) able to improve AST bioavailability in the brain. AST-SSLNs prepared by solvent-diffusion technique showed technological parameters suitable for parenteral administration (<200 nm). Formulated nanosystems were characterized by calorimetric studies, while their toxicological profile was evaluated by the MTT assay on the stem cell line OECs (Olfactory Ensheathing Cells). Furthemore, the protective effect of the nanocarriers was assessed by a long-term stability study and a UV stability assay confirming that the lipid shell of the nanocarriers was able to preserve AST concentration in the formulation. SSLNs were also capable of preserving AST’s antioxidant capacity as demonstrated in the oxygen radical absorbance capacity (ORAC) assay. In conclusion, these preliminary studies outline that SSLNs could be regarded as promising carriers for systemic administration of compounds such as AST aimed at AD treatment.

【 授权许可】

Unknown